Menu Search
Equities

Roivant Sciences Ltd

ROIV:NSQ

Roivant Sciences Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)11.87
  • Today's Change0.11 / 0.94%
  • Shares traded3.00m
  • 1 Year change+32.18%
  • Beta1.2274
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Roivant Sciences Ltd grew revenues 103.65% from 61.28m to 124.80m while net income improved from a loss of 1.01bn to a gain of 4.35bn.
Gross margin90.32%
Net profit margin2,916.27%
Operating margin2,799.07%
Return on assets106.95%
Return on equity149.26%
Return on investment126.66%
More ▼

Cash flow in USDView more

In 2024, Roivant Sciences Ltd increased its cash reserves by 287.12%, or 4.86bn. Cash Flow from Investing totalled 5.20bn, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 765.27m for operations while cash generated from financing totalled 419.36m.
Cash flow per share5.80
Price/Cash flow per share1.89
Book value per share7.35
Tangible book value per share7.17
More ▼

Balance sheet in USDView more

Roivant Sciences Ltd appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.74% of the market capitalization can be attributed to its 6.54bn and debt could be paid in full if management chose.
Current ratio27.91
Quick ratio27.75
Total debt/total equity0.0596
Total debt/total capital0.052
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.